Skip to main content

Commerce Supports Universal Commerce Protocol, Plans to Offer Buying Directly Across Google’s AI Surfaces

New standard creates a common language for agents and systems across the entire shopping journey from discovery and buying to post-purchase experiences AUSTIN, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) — Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced its endorsement of Google’s new Universal Commerce Protocol (UCP). The new, open-source standard creates a common language for agents and systems to work together across the entire shopping journey from discovery and buying to post-purchase experiences. So instead of building a new connection for every agent, they can all interact seamlessly providing merchants with a frictionless way to reach customers across the entire AI ecosystem. “AI...

Continue reading

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) — (Nasdaq: RXST) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition. Preliminary Unaudited Fourth Quarter and Full-year 2025 ResultsPreliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million, driven by:The sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®); representing a 10% increase in procedure volume compared to the third quarter of 2025; and The sale of 25 Light Delivery Devices (LDD™s), expanding...

Continue reading

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the month-12 follow-up timepoint demonstrating durable response to BB-301 HAYWARD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology...

Continue reading

Scatec signs landmark PPA in Egypt for 1.95 GW Solar and 3.9 GWh BESS capacity

Oslo/Cairo, 11 January 2026: Scatec ASA, a leading renewable energy solutions provider, has signed a Power Purchase Agreement (PPA) with the Egyptian Electricity Transmission Company (EETC) for a total capacity of 1.95 GW Solar and 3.9 GWh Battery Energy Storage Systems (BESS) in Egypt. Under the agreement Scatec will deliver one integrated Solar and BESS hybrid system designed to deliver continuous, around-the-clock renewable baseload power. In addition, Scatec will develop two standalone BESS projects aimed at providing essential grid stability and support services. The combined capacity will be the largest solar and BESS installation in Africa and the largest investment in Scatec’s history. “Signing this groundbreaking PPA further cements Scatec’s leading position and commitment to delivering reliable, renewable energy at a large scale...

Continue reading

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026 Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; tracking to IND-enabling studies in 2026 Strong balance sheet with cash, cash equivalents, and marketable securities of $208.9 million*, including proceeds from the equity financing, which is anticipated to close on January 13, 2026, and allows for continued investment...

Continue reading

VR Announces Further Upsize of Brokered Private Placement Led by Centurion One Capital to $2,750,000

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce a further upsize to its previously announced brokered private placement offering (the “Offering”). Pursuant to the upsize, the Company will now issue up to 17,187,500 units (the “Units) for aggregate gross proceeds of $2,750,000. Centurion One Capital Corp. (the “Lead Agent”) is acting as lead agent and sole bookrunner and maintains an option exercisable, in whole or in part, at the sole discretion of the Lead Agent, to sell up to $500,000 in additional Units pursuant to the Offering. As previously disclosed, each Unit will be offered at an issue price of $0.16 and will consist of one common...

Continue reading

Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Walmart Inc. (Nasdaq: WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 – the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (Nasdaq: AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq-100 Sustainable ESG Select™​ (NDXSES™), Nasdaq-100...

Continue reading

ReconAfrica Announces Adoption of Shareholder Rights Plan

CALGARY, Alberta, Jan. 09, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company”, “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) announces that the Board of Directors of the Company has adopted a Shareholder Rights Plan with Odyssey Trust Company as Rights Agent effective today. The Shareholder Rights Plan is consistent with modern rights plans adopted by other Canadian public companies and has not been adopted in response to any specific proposal or intention to acquire control of ReconAfrica. In the event of an unsolicited takeover bid in the future, the purpose of the Shareholder Rights Plan is to provide the Board and shareholders of ReconAfrica with an adequate amount of time to evaluate such unsolicited offer, explore value-enhancing alternatives, encourage potential bidders to treat...

Continue reading

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

– Rapidly transforming into a leading global biopharma company COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P. Morgan Healthcare Conference. “With our proven TransCon® technology platform, strong R&D capabilities, and a maturing commercial infrastructure and financial profile, Ascendis is rapidly transforming into a leading global biopharma company,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “Over the next year, this inflection will be driven by further global penetration and commercial expansion, a third potential TransCon...

Continue reading

Pan American Announces Extension to Marketing Program

CALGARY, Alberta, Jan. 09, 2026 (GLOBE NEWSWIRE) — Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS6) is pleased to announce, further to its news release on September 5, 2025, that it is extending its engagement of Upswitch Media Corp. (“Upswitch”) (email: info@upswitchmedia.com; phone number: 604-373-5875; address: 2709B 43rd Ave., Suite 1013, Vernon, British Columbia) for the provision of marketing services for an additional anticipated period of 60 days commencing on or about January 12, 2026, provided that the term of the marketing services may be extended or shortened at the discretion of management. Upswitch’s services are expected to include the creation of ad content and campaigns to raise awareness of the Company, provision of translation services, management of ad campaigns...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.